Completed PHASE2 INTERVENTIONAL 2-arm NCT01500720

Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy

Sponsor: Sanofi

Conditions Small Cell Lung Cancer

Interventions Cabazitaxel Topotecan

Updated 7 times since 2017 Last updated: Mar 30, 2015 Started: Mar 31, 2012 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Small Cell Lung Cancer and is currently completed. Sanofi leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Badalona, Spain , Barcelona, Spain , Brest, France , Budapest, Hungary , Caen, France , Cluj-Napoca, Romania , Craiova, Romania , Dnipropetrovsk, Ukraine , Donetsk, Ukraine and 40 more locations